PMV Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Operating expenses | $86.2M | $85.4M | $80.1M | $77.0M | $58.3M |
| Cash from operations | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Capital expenditure | $29,000 | $655,000 | $962,000 | $8.0M | $1.3M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
Shares outstanding 53.3M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.